Solbec progresses psoriasis trial
Tuesday, 05 October, 2004
Solbec Pharmaceuticals (ASX:SBP) has completed the first stage of its Phase I clinical trial for a psoriasis treatment based on its lead drug candidate SBP002.
The drug, formulated as a cream, was tested on a number of healthy individuals with no unwanted effects or reactions recorded. The company will now move on to test the treatment at a therapeutic dose, in preparation for larger Phase II trials, expected to commence after the Phase I trial winds up in early 2005.
The clinical trials are being conducted by clinical trials unit CMAX, part of listed Australian company IDT, in Adelaide.
SBP002 is also under investigation by Solbec as a cancer treatment for mesothelioma and melanoma.
MV Hondius passengers return to Australia under strict infection control measures
The Australian CDC has provided an update on hantavirus risk to Australians and infection...
$96m RNA Research and Manufacturing Facility opens in NSW
The new 4500 sqm RNA Research and Manufacturing Facility within the Macquarie University...
Cartherics and Catalent announce enhanced partnership
To support immune cell therapy products for the treatment of cancer and endometriosis, Australian...
